ArvinYangMD

Physician

Dr. Yang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2005 - 2008
Rutgers Robert Wood Johnson Medical SchoolClass of 2005

PubMed

15 citations
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.
John C O'Donnell, T Kim Le, Radu Dobrin, Mitch Higashi, Ashley Pereira
Future Oncology. 2021-01-01
50 citations
A Blueprint to Advance Colorectal Cancer Immunotherapies.
Dung T. Le, Vanessa M Hubbard-Lucey, Michael A. Morse, Christopher R. Heery, Andrea Dwyer
Cancer Immunology Research. 2017-11-01
2019 citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phas...
Jeffrey S. Weber, Sandra P. D'Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer
The Lancet. Oncology. 2015-04-01

Mersana Therapeutics Appoints Arvin Yang, M.D., Ph.D. As Senior Vice President and Chief Medical OfficerNovember 30th, 2020
Five-Year Survival Observed in Longest Follow-up to Date of Advanced Melanoma Patients Treated with the Combination of Opdivo (Nivolumab) and Yervoy (Ipilimumab)September 28th, 2019
Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data ShowsNovember 27th, 2018
Join now to see all